Acute effect of methylphenidate on QT interval duration and dispersion in children with attention deficit hyperactivity disorder

Advances in Therapy

Volumn 24, Issue 1, 2007, Pages 182-188

  Ilgenli, T Fikret ^a   Congologlu, Ayhan ^a   Ozturk, Cengiz ^b   Turkbay, Turner ^c   Akpinar, Onur ^a   Kilicaslan, Fethi ^c  

^a Golcuk Army Hospital   (Turkey)

^b Eskisehir Army Hospital   (Turkey)

^c GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

Electrocardiography; Methylphenidate; QT dispersion

Indexed keywords

LEAD; METHYLPHENIDATE;

ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CLINICAL ARTICLE; DRUG EFFECT; ELECTROCARDIOGRAM; FEMALE; HUMAN; MALE; QT DISPERSION; STATISTICAL SIGNIFICANCE;

ADOLESCENT; ARRHYTHMIA; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BLOOD PRESSURE; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROCARDIOGRAPHY; FEMALE; HEART RATE; HUMANS; MALE; METHYLPHENIDATE; OXYGEN CONSUMPTION;

EID: 34247874592     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02850007     Document Type: Article

References (25)

1. Safer DJ, Zito, JM, Fine EM. Increased methylphenidate usage for attention deficit disorder in the 1990s. Pediatrics. 1996;98:1084-1088.
2. Solanto MV. Neuropsychopharmacological mechanisms of stimulant drug action in attention deficit hyperactivity disorder: a review and integration. Behav Brain Res. 1998;94:127-152.
3. Hinshaw S, Heller T, McHale JP. Covert antisocial behavior in boys with attention-deficit/hyperactivity disorder: external validation and effects of methylphenidate. J Consult Clin Psychol. 1992;60:274-281.
4. RapoportJL, Inoff-Germain G. Responses to methylphenidate in attention-deficit/hyperactivity disorder and normal children: update 2002. J Attention Disord. 2002;1:57-60.
5. Nissen SE. ADHD drugs and cardiovascular risk. N Engl J Med. 2006;354:1445-1448.
6. Turkmen M, Barutcu I, Esen AM, et al. Assessment of QT interval duration and dispersion in athlete's heart. J Intern Med Res. 2004;32:626-632.
7. Mirvis DM, Goldberger AL. Electrocardiography. In: Braunwald E, Zipes DP, Libby P, eds. Heart Disease, 6th ed. Philadelphia, Pa: WB Saunders; 2001:82-128.
8. Alpaslan M, Onrat E, Yilmazer M, Fenkci V. QT dispersion in patients with polycystic ovary syndrome. Jpn Heart J. 2002;43:487-493.
9. Gracious BL. Atrioventricular nodal re-tachycardia associated with stimulant treatment. J Child Adolesc Psychopharmacol. 1999;9:125-128.
10. Lucas PB, Gardner DL, Wolkowitz OM, Tucker EE, Cowdry RW. Methylphenidate-induced cardiac arrhythmias. N Engl J Med. 1986;315:1485.
11. Langlois Y. Ventricular tachycardia associated with methylphenidate. Can Med Assoc J. 1968;98:698.
12. Turgay A. DSM-IV-Based Child and Adolescent Behavior Disorders Screening and Rating Scale (unpublished). Toronto, Ontario, Canada: Integrative Therapy Institute; 1995.
13. Ahnve S. Correction of QT interval for heart rate: review of different formulas and the use of Bazett's formula in myocardial infarction. Am Heart J. 1985;109:568-574.
14. Lazar J, Manzella S, Moonjelly J, Wirkowski E, Cohen TJ. The prognostic value of QT dispersion in patients presenting with acute neurological events. J Invasive Cardiol. 2003;15:31-35.
15. Kuo CS, Redy CP, Munakata K, Surawicz B. Mechanism of ventricular arrhythmia caused by increased dispersion of repolarization. Eur Heart J. 1985;6:63-71.
16. Paventi S, Bevilacqua U, Parafati MA, Di Luzio E, Rossi F, Pelliccioni PR. QT dispersion and early arrhythmic risk during acute myocardial infarction. Angiology. 1999;50:209-215.
17. Algra A, Tijssen JG, Roelandt JR, Pool J, Lubsen J. QTc prolongation measured by standard 12-lead electrocardiography is an independent risk for sudden cardiac death due to cardiac arrest. Circulation. 1991;83:1888-1894.
18. Macfarlane PW, McLaughlin SC, Rodger JC. Influence of lead selection and population on automated measurement of QT dispersion. Circulation. 1998;98:2160-2167.
19. Ileri M, Yetkin E, Tandogan I, et al. Effect of habitual smoking on QT interval duration and dispersion. Am J Cardiol. 2001;88:322-325.
20. Murray A, McLaughlin NB, Campbell RW. Measuring QT dispersion: man versus machine. Heart. 1997;77:539-542.
21. Patrick KS, Caldwell RW, Ferris RM, Breese GR. Pharmacology of the enantiomers of threo-methylphenidate. J Pharmacol Exp Ther. 1987;241:152-158.
22. Aoyama T, Kotaki H, Honda Y, Nakagawa F. Kinetic analysis of enantiomers of threo-methylphenidate and its metabolite in two healthy subjects after oral administration as determined by a gas chromatographic-mass spectrometric method. J Pharm Sci. 1990;79:465-459.
23. Faraj BA, Israili ZH, Perel JM, et al. Metabolism and disposition of methylphenidate-C14: studies in man and animals. J Pharmacol Exp Ther. 1974;191:535-547.
24. Ballard JE, Boileau RA, Sleator EK, Massey BH, Sprague RL. Cardiovascular responses of hyperactive children to methylphenidate. JAMA. 1976;236:2870-2874.
25. Lee S, Harris ND, Robinson RT, Yeoh L, Macdonald IA, Heller SR. Effects of adrenaline and potassium on QTc interval and QT dispersion in man. Eur J Clin Invest. 2003;33:93-98.